Clinical Trial Update: Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of orelabrutinib and obinutuzumab in previously untreated marginal zone lymphoma is currently recruiting in Ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING